These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31688405)

  • 1. Pramipexole and Selegiline Combination Therapy in a Case of Treatment-Resistant Depression.
    Moirand R; Galvao F; Dondé C
    J Clin Psychopharmacol; 2019; 39(6):684-685. PubMed ID: 31688405
    [No Abstract]   [Full Text] [Related]  

  • 2. Selegiline transdermal system Somerset.
    Mahmood I
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal selegiline: a novel MAOI formulation for depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2006 Jul; 44(7):9-12. PubMed ID: 17310829
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
    Fawcett J; Rush AJ; Vukelich J; Diaz SH; Dunklee L; Romo P; Yarns BC; Escalona R
    Am J Psychiatry; 2016 Feb; 173(2):107-11. PubMed ID: 26844792
    [No Abstract]   [Full Text] [Related]  

  • 6. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
    Wang JCC; Swainson J
    J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
    [No Abstract]   [Full Text] [Related]  

  • 7. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
    Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
    J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline transdermal system in major depressive disorder: profile report.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230
    [No Abstract]   [Full Text] [Related]  

  • 10. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS; Amsterdam JD
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline transdermal system: in the treatment of major depressive disorder.
    Frampton JE; Plosker GL
    Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
    Carlat DJ
    Psychopharmacol Bull; 2007; 40(3):29-31. PubMed ID: 18007566
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study.
    Tundo A; Betro' S; Iommi M; de Filippis R
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jan; 112():110425. PubMed ID: 34375683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
    Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
    J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal selegiline in patients receiving electroconvulsive therapy.
    Horn PJ; Reti I; Jayaram G
    Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discussion: a fresh look at monoamine oxidase inhibitors for depression.
    Cohen LJ; Sclar DA; Culpepper L; Flockhart DA; Hirschfeld RM; Thase ME; VanDenBerg CM
    J Clin Psychiatry; 2012; 73 Suppl 1():42-5. PubMed ID: 22951242
    [No Abstract]   [Full Text] [Related]  

  • 19. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 20. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.